Planning and evaluation is an active process at the Ohio State University Comprehensive Cancer Center. A University-based long range plan is being developed and carried out by a renowned management consulting firm, Deloitte and Touche. The planning effort culminated in a retreat of the Project Steering Committee which identified the key issues for a five year plan. The strategic plan for the CCC-CHRI resulted from this planning process. The key areas of the plan are research, patient care, education, organization and management, human and financial resources. The External Advisory Committee (EAC) is composed of Dr. Carlo Croce, Dr. C. Russell de Burlo, Dr. Richard Rifkind, Dr. Thomas R. Tritton, Dr. Frederick Valeriote, Dr. Daniel Van Hoff and Dr. Ernst L. Wynder. This distinguished group meets annually to discuss planning, management of programs, and administration. The Committee reports directly to Dr. Schuller but meets also with Center Senior Leaders and University officials during its annual site visit. The Internal Advisory Committee (IAC) consists of Deans of the various Colleges in which the OSUCCC Programs are conducted. This committee, which is chaired by the Associate Vice President for Health Services, Dr. Ronald L. St. Pierre, meets three times yearly. The CCC-member advisory committees include the Committees for Space Allocation, Basic Research, Clinical Research, Community Research, Research Development Award Committee, and Clinical Scientific Review Committee.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-24
Application #
6268868
Study Section
Project Start
1998-07-01
Project End
1999-11-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
24
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
Barajas, Juan M; Reyes, Ryan; Guerrero, Maria J et al. (2018) The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular cancer. Sci Rep 8:9105

Showing the most recent 10 out of 2602 publications